Skip to content
Screener

Interest Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$6.21M+18.1%
Biogen logo
BiogenBIIB
$25.3M-21.7%
Regenxbio logo
RegenxbioRGNX
$1.22M-63.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$8.76M+23.3%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$5.1M-1.1%
Wave Life Sciences logo
Wave Life SciencesWVE
$4.72M+99.1%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$917.85M+94.8%
Enterprise value$778.61M+119%

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337935
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses57,38441,693114,69281,745
Loss from operations(57,384)(41,693)(114,692)(81,745)
Other income, net:
Interest income3,2212,9665,2855,266
Interest expense(60)(128)
Change in fair value of derivative liabilities(850)(900)(2,500)(2,550)
Other income, net214207371395
Total other income, net2,5852,2133,1562,983

Item 1. Financial Statements (unaudited)

FAQ

What is Solid Biosciences Inc.'s interest income?
Solid Biosciences Inc. (SLDB) reported interest income of $3.22M in Q2 2026.
How has Solid Biosciences Inc.'s interest income changed year-over-year?
Solid Biosciences Inc.'s interest income increased by 8.6% year-over-year, from $2.97M to $3.22M.
What is the long-term trend for Solid Biosciences Inc.'s interest income?
Over 4 years (2021 to 2025), Solid Biosciences Inc.'s interest income has grown at a 252.7% compound annual growth rate (CAGR), from $64K to $9.9M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Solid Biosciences Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude